Novo Nordisk Ozempic trial delays progression of chronic kidney disease-February 2024-www.financetom.com

Novo Nordisk Ozempic trial delays progression of chronic kidney disease

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Novo Nordisk Ozempic trial delays progression of chronic kidney disease

Mar 5, 2024 2:27 AM

OSLO, March 5 (Reuters) - Novo Nordisk's

widely used diabetes drug Ozempic delayed progression of chronic

kidney disease in diabetes patients, according to a large

late-stage study.

"The trial achieved its primary endpoint by

demonstrating a statistically significant and superior reduction

in kidney disease progression, major adverse cardiovascular

events (MACE) and death of 24%," it said in a statement.

Previous page： Silver One Resources Completes Geophysical Survey on Phoenix Project in Arizona Next page： TransAlta Fourth-Quarter Loss Narrows on Revenue Gain; Hikes Dividend 8%, Issues 2025 Guidance

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Silver One Resources Completes Geophysical Survey on Phoenix Project in Arizona

Feb 20, 2025

08:31 AM EST, 02/20/2025 (MT Newswires) -- Silver One Resources ( SLVRF ) said overnight Wednesday that it completed the geophysical processing and 3D modelling of helicopter-borne electromagnetic data from its ZTEM survey in October 2024 at the Phoenix silver project in Arizona. According to Silver One, Geotech's processing, 3D-modelling, and targeting analysis identified several significant anomalies potentially related to...

TransAlta Fourth-Quarter Loss Narrows on Revenue Gain; Hikes Dividend 8%, Issues 2025 Guidance

Feb 20, 2025

08:30 AM EST, 02/20/2025 (MT Newswires) -- TransAlta ( TAC ) on Thursday said its fourth-quarter loss narrowed on higher revenue as it boosted its dividend by 8% and issued 2025 guidance. The power company said it lost $65 million, or $0.22 per share, in the period, compared with a loss of $84 million, or $0.27, in the year-prior quarter....

Sabre's Q4 Adjusted Loss Narrows, Revenue Rises; Provides 2025 Revenue Guidance

Feb 20, 2025

08:33 AM EST, 02/20/2025 (MT Newswires) -- Sabre (SABR) reported a Q4 adjusted loss Thursday of $0.08 per diluted share, narrowing from a loss of $0.12 a year earlier. Analysts polled by FactSet expected an adjusted loss of $0.10. Revenue for the quarter ended Dec. 31 was $714.7 million compared with $687.1 million a year earlier. Four analysts surveyed by...

Builders FirstSource misses quarterly estimates as fewer new homes built

Feb 20, 2025

Feb 20 (Reuters) - Builders FirstSource Inc ( BLDR ) reported quarterly revenue below expectations on Thursday, pressured by fewer constructions of single- and multi-family homes as well as lower selling prices for building materials. Shares of the Irving, Texas-based construction supplies company were down 3.7% in trading before the bell. Many potential homebuyers remain reluctant to buy due to...